Protalix BioTherapeutics
PLX
PLX
34 hedge funds and large institutions have $6.04M invested in Protalix BioTherapeutics in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
1.92% less ownership
Funds ownership: 7.04% → 5.12% (-1.9%)
Holders
34
Holding in Top 10
–
Calls
$3.4M
Puts
$235K
Top Buyers
| 1 | +$2.07M | |
| 2 | +$386K | |
| 3 | +$333K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$316K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$183K |
Top Sellers
| 1 | -$3.31M | |
| 2 | -$110K | |
| 3 | -$22.9K | |
| 4 |
SSWM
Smith Salley Wealth Management
Greensboro,
North Carolina
|
-$16.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.16K |